High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

Karen K. Yam; Erica Gipson; Marina Klein; Sharon Walmsley; David Haase; Scott Halperin; David Scheifele; Brian J. Ward; Curtis Cooper

doi:10.1007/s10875-014-0054-z

High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03_A) Influenza Vaccine

Karen K. Yam, Erica Gipson, Marina Klein, Sharon Walmsley, David Haase, Scott Halperin, David Scheifele, Brian J. Ward, Curtis Cooper

Economics, Econometrics and Finance

科研成果: 期刊稿件 › 文章 › 同行评审

7 引用（Scopus）

源语言	英语
页（从-至）	655-662
页数	8
期刊	Journal of Clinical Immunology
卷	34
期	6
DOI	https://doi.org/10.1007/s10875-014-0054-z
出版状态	已出版 - 8月 1 2014

!!!ASJC Scopus Subject Areas

免疫学和过敏症
免疫学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s10875-014-0054-z

其它文件与链接

引用此

@article{c9e3f80662d147d1b120047e3a21818d,

title = "High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine",

author = "Yam, {Karen K.} and Erica Gipson and Marina Klein and Sharon Walmsley and David Haase and Scott Halperin and David Scheifele and Ward, {Brian J.} and Curtis Cooper",

note = "Funding Information: Acknowledgments This study was funded by the Canadian Institutes of Health Research and the Public Health Agency of Canada through the PHAC/CIHR Influenza Research Network (PCIRN; CIHR grant 96974). Additional funding and logistical support was provided by the CIHR Canadian HIV Trials Network (CTN 253). Drs. Cooper and Walmsley acknowledge support as Ontario HIV Treatment Network Career Scientists. Elizabeth Allen is acknowledged for technical support. The authors declare that they have no conflict of interest. Publisher Copyright: {\textcopyright} 2014, Springer Science+Business Media New York.",

year = "2014",

month = aug,

day = "1",

doi = "10.1007/s10875-014-0054-z",

language = "English",

volume = "34",

pages = "655--662",

journal = "Journal of Clinical Immunology",

issn = "0271-9142",

publisher = "Springer New York",

number = "6",

}

TY - JOUR

T1 - High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

AU - Yam, Karen K.

AU - Gipson, Erica

AU - Klein, Marina

AU - Walmsley, Sharon

AU - Haase, David

AU - Halperin, Scott

AU - Scheifele, David

AU - Ward, Brian J.

AU - Cooper, Curtis

N1 - Funding Information: Acknowledgments This study was funded by the Canadian Institutes of Health Research and the Public Health Agency of Canada through the PHAC/CIHR Influenza Research Network (PCIRN; CIHR grant 96974). Additional funding and logistical support was provided by the CIHR Canadian HIV Trials Network (CTN 253). Drs. Cooper and Walmsley acknowledge support as Ontario HIV Treatment Network Career Scientists. Elizabeth Allen is acknowledged for technical support. The authors declare that they have no conflict of interest. Publisher Copyright: © 2014, Springer Science+Business Media New York.

PY - 2014/8/1

Y1 - 2014/8/1

UR - http://www.scopus.com/inward/record.url?scp=84939885947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939885947&partnerID=8YFLogxK

U2 - 10.1007/s10875-014-0054-z

DO - 10.1007/s10875-014-0054-z

M3 - Article

C2 - 24824648

AN - SCOPUS:84939885947

SN - 0271-9142

VL - 34

SP - 655

EP - 662

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

IS - 6

ER -